跳至主要内容
临床试验/NCT02093065
NCT02093065已完成不适用

Decreased Platelet Function as a Cause of Increased Bleeding in Patients With Hemophilia A

Boston Children's Hospital1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2015年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
36
试验地点
1
主要终点
The percentage of coated platelets.

研究概览

简要总结

Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males. Hemophilia A patients are classified into 3 different categories based on residual FVIII activity compared to normal: mild (6-40%), moderate (1-5%) and severe (<1%). This categorization correlates to some degree with bleeding phenotype, but does not completely define it. Some patients with hemophilia A bleed less often than others despite identical plasma FVIII levels. The cause(s) of this phenotype heterogeneity in hemophilia A remains largely unknown, despite a number of studies of possible factors.

Activated platelets, in addition to their role in primary hemostasis, play a major role in secondary hemostasis (coagulation) by providing a phospholipid surface to which coagulation factors bind. A role for platelets in the hemorrhagic propensity of hemophilia A has been suggested in the past, but only a small number of studies have been performed with limitations in assays performed and numbers of patients. The purpose of the present study is to determine whether platelet reactivity in severe hemophilia A patients is associated with past bleeding frequency and/or predicts future bleeding frequency.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Years 至 18 Years(Child, Adult)
性别
Male
接受健康志愿者

入选标准

  • Patients with severe hemophilia A who are being prophylactically treated with FVIII.
  • Age of at least 2 years.
  • Bleeding history of at least 6 months.
  • IRB-approved informed consent.

排除标准

  • Presence of FVIII inhibitors.
  • Greater than 7 days since active bleeding.

结局指标

主要结局

The percentage of coated platelets.

时间窗: 2 years

次要结局

  • The number of procoagulant platelet-derived microparticles.(2 years)
  • Platelet reactivity.(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alan D. Michelson

Professor of Pediatrics and Professor of Medicine, Harvard Medical School Director, Center for Platelet Research Studies Director, Thrombosis and Anticoagulation Program Boston Children's Hospital / Dana-Farber Cancer Institute

Boston Children's Hospital

研究点 (1)

Loading locations...

相似试验